Scabies and pediculosis pubis: An update of treatment regimens and general review

Clinical Infectious Diseases

Volumn 35, Issue , 2002, Pages S146-S151

  Wendel, Karen ^a   Rompalo, Anne ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTICIN; BENZYL BENZOATE; CROTAMITON; IVERMECTIN; LINDANE; MALATHION; PERMETHRIN; PIPERONYL BUTOXIDE; PYRETHROID;

APLASTIC ANEMIA; CONVULSION; DIARRHEA; DRUG EFFICACY; ECTOPARASITE; ENDEMIC DISEASE; HUMAN; MORBIDITY; PARASITE TRANSMISSION; PEDICULUS; PRIORITY JOURNAL; PRURITUS; PUBIC PEDICULOSIS; RASH; REVIEW; SCABIES;

ANTHELMINTICS; HUMANS; INSECTICIDES; IVERMECTIN; LICE INFESTATIONS; LINDANE; PERMETHRIN; PIPERONYL BUTOXIDE; PYRETHRINS; SCABIES;

EID: 0037108507     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342102     Document Type: Review

References (52)

1. Mathisen GE. Of mites and men-lessons in scabies for the infectious diseases clinician. Clin Infect Dis 1998; 27:646-8.
2. Burkhart CG, Burkhart CN, Burkhart KM. An epidemiologic and therapeutic reassessment of scabies. Cutis 2000; 65:233-40.
3. Mimouni D, Gdalevich M, Mimouni FB, Haviv J, Ashkenazi I. The epidemiologic trends of scabies among Israeli soldiers: a 28-year follow-up. Int J Dermatol 1998; 37:586-7.
4. Christophersen J. The epidemiology of scabies in Denmark, 1900 to 1975. Arch Dermatol 1978; 114:747-50.
5. Kimchi N, Green MS, Stone D. Epidemiologic characteristics of scabies in the Israel Defense Force. Int J Dermatol 1989; 28:180-2.
6. Downs AM, Harvey I, Kennedy CT. The epidemiologv of head lice and scabies in the UK. Epidemiol Infect 1999; 122:471-7.
7. Holness DL, DeKoven JG, Nethercott JR. Scabies in chronic health care institutions. Arch Dermatol 1992; 128:1257-60.
8. Alberici F, Pagani L, Ratti G, Viale P. Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies. Br J Dermatol 2000; 142:969-72.
9. Chosidow O. Scabies and pediculosis. Lancet 2000; 355:819-26.
10. Walton SF, McBroom J, Mathews JD, Kemp DJ, Currie BJ. Crusted scabies: a molecular analysis of Sarcoptes scabiei variety hominis populations from patients with repeated infestations. Clin Infect Dis 1999; 29:1226-30.
11. Hashimoto K, Fujiwara K, Punwaney J, et al. Post-scabetic nodules: a lymphohistiocytic reaction rich in indeterminate cells. J Dermatol 2000; 27:181-94.
12. Currie B, Huffam S, O'Brien D, Walton S. Ivermectin for scabies. Lancet 1997; 350:1551.
13. Adjei O, Brenya RC. Secondary bacterial infection in Ghanaian patients with scabies. East Afr Med J 1997; 74:729-31.
14. Jarrett P, Snow J. Scabies presenting as a necrotizing vasculitis in the presence of lupus anticoagulant. Br J Dermatol 1998; 139:701-3.
15. Valks R, Buezo GF, Dauden E. Scabies and leukocytoclastic vasculitis in an HIV-seropositive man. Int J Dermatol 1996; 35:605-6.
16. Micali G, Lacarrubba F, Lo GG. Scraping versus videodermatoscopy for the diagnosis of scabies: a comparative study. Acta Derm Venereol 1999; 79:396.
17. Argenziano G, Fabbrocini G, Delfino M. Epiluminescence microscopy. A new approach to in vivo detection of Sarcoptes scabiei. Arch Dermatol 1997; 133:751-3.
18. Arlian LG, Estes SA, Vyszenski-Moher DL. Prevalence of Sarcoptes scabiei in the homes and nursing homes of scabietic patients. J Am Acad Dermatol 1988; 19:806-11.
19. Estes SA, Arlian L. Survival of Sarcoptes scabiei. J Am Acad Dermatol 1981; 5:343.
20. Arlian LG, Runyan RA, Achar S, Estes SA. Survival and infectivity of Sarcoptes scabiei var. canis and var. hominis. J Am Acad Dermatol 1984; 11:210-5.
21. Ong GP, Bhatia SG. Survival of Sarcoptes scabiei. J Am Acad Dermatol 1982; 6:115-6.
22. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2002. MMWR Morb Mortal Wkly Rep 2002;51(RR-6):67-9.
23. Thomson Healthcare. 2001 drug topics red book. 105th ed. Montvale, NJ: Medical Economics Company, 2001.
24. Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000;42:236-40.
25. Chouela EN, Abeldano AM, Pellerano G, et al. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol 1999; 135:651-5.
26. Conti Diaz IA, Amaro J. Treatment of human scabies with oral ivermectin. Rev Inst Med Trop Sao Paulo 1999; 41:259-61.
27. Dourmishev A, Serafimova D, Dourmishev L. Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol 1998; 11:247-51.
28. Elmogy M, Fayed H, Marzok H, Rashad A. Oral ivermectin in the treatment of scabies. Int J Dermatol 1999; 38:926-8.
29. Offidani A, Cellini A, Simonetti O, Fumelli C. Treatment of scabies with ivermectin. Eur J Dermatol 1999; 9:100-1.
30. Huffam SE, Currie BJ. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis 1998; 2:152-4.
31. Yeruham I, Hadani A. Control of human scabies by topical application of ivermectin. Ann Trop Med Parasitol 1998; 92:627-9.
32. Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg 2000; 94:92-6.
33. Bockarie MJ, Alexander ND, Kazura JW, Bockarie F, Griffin L, Alpers MP. Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. Acta Trop 2000; 75:127-30.
34. Dannaoui E, Kiazand A, Piens M, Picot S. Use of ivermectin for the management of scabies in a nursing home. Eur J Dermatol 1999; 9:443-5.
35. Sullivan JR, Watt G, Barker B. Successful use of ivermectin in the treatment of endemic scabies in a nursing home. Australas J Dermatol 1997; 38:137-40.
36. Schultz MW, Gomez M, Hansen RC, et al. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. Arch Dermatol 1990; 126:167-70.
37. Elgart ML. A risk-benefit assessment of agents used in the treatment of scabies. Drug Saf 1996; 14:386-93.
38. Walker GJ, Johnstone PW. Interventions for treating scabies. Cochrane Database Syst Rev 2000; 3:CD000320.
39. WHO 98. Abstracted from: WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden. Reported adverse reactions to ectoparasiticiodes, incl. scabicides, insecticides and repellents. 1998.
40. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997; 349:1144-5.
41. Reintjes R, Hoek C. Deaths associated with ivermectin for scabies. Lancet 1997; 350:215.
42. Boix V, Sanchez-Paya J, Portilla J, Merino E. Nosocomial outbreak of scabies clinically resistant to lindane. Infect Control Hosp Epidemiol 1997; 18:677.
43. Taplin D, Meinking TL, Porcelain SL, Castillero PM, Chen JA. Permethrin 5% dermal cream: a new treatment for scabies. J Am Acad Dermatol 1986; 15:995-1001.
44. Moustafa EH, el Kadi MA, al Zeftawy AH, Singer HM, Khalil KA. The relation between scabies and hypersensitivity to antigens of house dust mites and storage mites. J Egypt Soc Parasitol 1998; 28:777-87.
45. Maunder JW. Lice and scabies. Myths and reality. Dermatol Clin 1998; 16:843-5.
46. National guideline for the management of Phthirus pubis infestation. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999;75(Suppl 1):S78-9.
47. Budak S, Ilhan F, Guruz AY. A comparative study on the efficacy of 0.4% sumithrine and 1% lindane in the treatment of Pediculus humanus capitis in Turkey. J Egypt Soc Parasitol 1996; 26:237-41.
48. Bainbridge CV, Klein GL, Neibart SI, et al. Comparative study of the clinical effectiveness of a pyrethrin-based pediculicide with combing versus a permethrin-based pediculicide with combing. Clin Pediatr (Phila) 1998; 37:17-22.
49. Fan PC, Chung WC, Fan CK, Huang P, Yen CW. Prevalence and treatment of pediculus capitis infestation among aboriginal school children in northern Taiwan. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1999; 15:209-17.
50. Downs AM, Stafford KA, Harvey I, Coles GC. Evidence for double resistance to permethrin and malathion in head lice. Br J Dermatol 1999; 141:508-11.
51. Pollack RJ, Kiszewski A, Armstrong P, et al. Differential permethrin susceptibility of head lice sampled in the United States and Borneo. Arch Pediatr Adolesc Med 1999; 153:969-73.
52. Picollo MI, Vassena CV, Casadio AA, Massimo J, Zerba EN. Laboratory studies of susceptibility and resistance to insecticides in pediculus capitis. J Med Entomol 1998; 35:814-7.